Completed PHASE2 INTERVENTIONAL 2-arm NCT00481013

Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy (VALIANTSMA)

Prospective Controlled Trial of Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy (VALIANTSMA) Study

Sponsor: Abbott

Interventions Placebo Valproic Acid (VPA)

Updated 6 times since 2017 Last updated: Dec 5, 2016 Started: Jul 31, 2007 Primary completion: Dec 31, 2009 Completion: Nov 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00481013, this PHASE2 trial focuses on Spinal Muscular Atrophy and remains completed. Sponsored by Abbott, it has been updated 6 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
Families of Spinal Muscular Atrophy
University of Utah

Data source: University of Utah

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Columbus, United States